Clinical outcome correlation of positron emission tomography (PET) in patients with locally advanced breast cancer (LABC) treated with neoadjuvant doxorubicin and docetaxel

Khan, Ali; Dickler, Adam; Marcus, Elizabeth A.; Coon, John S.; Ali, Amjad; Babbo, Angela; Gupta-Burt, Shalina

doi:10.1016/s0360-3016(03)00949-0

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The size of residual lymph node mass on CT had no correlation with the pathological findings in this study. In 10 of the 20 patients of locally advanced breast cancer, who were treated with chemotherapy and had a negative PET scan, only one instance recurrence was observed which was at a distant site [17].…”

Section: Discussionmentioning

confidence: 99%

Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET

Berkowitz

Basu²,

Srinivas

et al. 2008

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET

Berkowitz

Basu²,

Srinivas

et al. 2008

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…However, whilst other assessment modalities, such as ultrasound examination [14,20], magnetic resonance mammography [20,21] and positron emission tomography [22], may indicate which patients are most likely to have no residual tumour, following completion of primary chemotherapy, well designed clinical trials are required to confirm this.…”

Section: Discussionmentioning

confidence: 99%

Patterns of Local and Distant Disease Relapse in Patients with Breast Cancer Treated with Primary Chemotherapy: Do Patients with a Complete Pathological Response Differ from Those with Residual Tumour in the Breast?

Chaturvedi

Mclaren

Schofield

et al. 2005

Breast Cancer Res Treat

View full text Add to dashboard Cite

This study aimed to evaluate patterns of local and distant disease recurrence in patients having primary chemotherapy and compared patterns of relapse in patients with a complete pathological response with those who had residual breast disease. This is an observational study using a sequential series of patients treated with primary chemotherapy. They were followed up for a minimum of 5 years. All data was collected prospectively. Three hundred forty-one consecutive patients with breast cancer were treated with up to eight cycles of doxorubicin-based chemotherapy. Clinical and pathological response rates were evaluated and patients were followed up for disease recurrence (local and distant) and overall survival. Fifty-two patients (16.5%) had a complete pathological response to chemotherapy. Distant disease recurrence occurred in nine patients (17.3%) but no local recurrence was observed. In patients not having a complete pathological response, 86 patients (32.6%) subsequently developed metastases. Local recurrence of disease occurred in 12 (4.5%). There was a statistically significant difference in overall survival between patients whose tumours had a complete pathological response compared with patients who had residual disease in the breast following chemotherapy (88% versus 70% at 5 years, p = 0.036). Following primary chemotherapy, about 84% of patients had residual disease in the breast. Surgery is necessary to ensure complete removal of residual tumour and excellent rates of local control are achievable. A complete pathological response is associated with fewer local and distant recurrences as well as improved survival although there are no differences in time to development of metastatic relapse.

show abstract

Clinical outcome correlation of positron emission tomography (PET) in patients with locally advanced breast cancer (LABC) treated with neoadjuvant doxorubicin and docetaxel

Cited by 2 publications

References 0 publications

Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET

Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET

Patterns of Local and Distant Disease Relapse in Patients with Breast Cancer Treated with Primary Chemotherapy: Do Patients with a Complete Pathological Response Differ from Those with Residual Tumour in the Breast?

Contact Info

Product

Resources

About